Molecular dissection of Chagas induced cardiomyopathy reveals central disease associated and druggable signaling

Jacob M Wozniak1,2, Tatiana Araújo Silva3, Diane Thomas1

  • 1Skaggs School of Pharmacy and Pharmaceutical Sciences; University of California San Diego; La Jolla, CA, United States of America.

Insights

This study reveals key host protein changes in the heart during Chagas disease (T. cruzi infection). Researchers identified potential therapeutic targets, including mitochondrial proteins and kinases, for treating chronic Chagas disease.

Area of Science:

  • Proteomics and host-pathogen interactions
  • Cardiovascular disease research
  • Infectious disease molecular mechanisms

Background:

  • Chagas disease, caused by T. cruzi infection, leads to severe cardiac complications in chronic stages.
  • Current treatments for chronic Chagas disease are limited, necessitating new therapeutic targets.
  • Understanding host signaling in cardiac tissue is crucial for developing effective interventions.

Purpose of the Study:

  • To identify host signaling events in heart tissue during Chagas disease using quantitative proteomics.
  • To define the host proteome and phospho-proteome response to T. cruzi infection in the heart.
  • To uncover potential therapeutic targets for chronic Chagas disease.

Main Methods:

  • Quantitative, multiplexed proteomics and phospho-proteomics on heart tissues from a Chagas disease mouse model.
  • Bioinformatic analysis of kinase activity and proteomic profiles.
  • Linking proteomic data to known therapeutic interventions.

Main Results:

  • Proteome analysis revealed increased immune response and repression of mitochondrial proteins.
  • Phospho-proteomics identified alterations in plasma membrane and cytoskeletal proteins.
  • Bioinformatics indicated activation of NDRG2, JNK/p38, DYRK2, and AMPKA2 kinases, with inhibition of casein kinases.

Conclusions:

  • This study provides the first molecular insight into host proteome and phospho-proteome responses in the heart during T. cruzi infection.
  • Identified potential therapeutic targets include mitochondrial proteins, immune effectors, and specific kinases.
  • These findings highlight pathways for further validation as drug targets for chronic Chagas disease treatment.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
329
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
277
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
389
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
347
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
270
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
278